GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II drugs for Malignant Mesothelioma have a 42% phase ...

AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase 3 trial. The trial showed Lynparza (olaparib) demonstrated sustained ...

--(BUSINESS WIRE)--Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA ® (olaparib) demonstrated ...

Lynparza reduced the risk of death by 28% ... Also Read: After Lung Cancer Approval, AstraZeneca’s Imfinzi Goes Under FDA Priority Review For Bladder Cancer At a median follow-up of 6.1 years ...

AstraZeneca (NASDAQ:AZN) and Merck (NYSE:MRK) said long-term data from a Phase 3 study showed that 87.5% of patients treated with their breast cancer drug Lynparza were still alive six years later ...

AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase 3 trial. The trial showed Lynparza (olaparib) demonstrated sustained, ...

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Two years ago, LYNPARZA became the first and only PARP inhibitor to demonstrate a survival benefit in germline BRCA ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on AZN: AstraZeneca NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results from the OlympiA Phase 3 trial which showed LYNPARZA(olaparib ...